HK1209725A1 - Bendamustine derivatives and related compounds, and medical use thereof cancer therapy - Google Patents

Bendamustine derivatives and related compounds, and medical use thereof cancer therapy

Info

Publication number
HK1209725A1
HK1209725A1 HK15110327.6A HK15110327A HK1209725A1 HK 1209725 A1 HK1209725 A1 HK 1209725A1 HK 15110327 A HK15110327 A HK 15110327A HK 1209725 A1 HK1209725 A1 HK 1209725A1
Authority
HK
Hong Kong
Prior art keywords
cancer therapy
related compounds
medical use
bendamustine
bendamustine derivatives
Prior art date
Application number
HK15110327.6A
Other languages
English (en)
Chinese (zh)
Inventor
‧吕貝
‧霍夫邁爾
‧席卡內德
‧席卡内德
‧布沙爾
‧伯納特
‧胡貝爾
‧利默特
Original Assignee
Schickaneder Elmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schickaneder Elmut filed Critical Schickaneder Elmut
Publication of HK1209725A1 publication Critical patent/HK1209725A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15110327.6A 2012-06-19 2015-10-21 Bendamustine derivatives and related compounds, and medical use thereof cancer therapy HK1209725A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661374P 2012-06-19 2012-06-19
US201261670158P 2012-07-11 2012-07-11
PCT/EP2013/062347 WO2013189847A1 (en) 2012-06-19 2013-06-14 Bendamustine derivatives and related compounds, and medical use thereof cancer therapy

Publications (1)

Publication Number Publication Date
HK1209725A1 true HK1209725A1 (en) 2016-04-08

Family

ID=48628661

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110327.6A HK1209725A1 (en) 2012-06-19 2015-10-21 Bendamustine derivatives and related compounds, and medical use thereof cancer therapy

Country Status (13)

Country Link
US (2) US10526290B2 (pt)
EP (1) EP2861564B1 (pt)
JP (1) JP6153606B2 (pt)
KR (1) KR101955065B1 (pt)
CN (1) CN104395296A (pt)
BR (1) BR112014031556B1 (pt)
CA (1) CA2875455C (pt)
ES (1) ES2694757T3 (pt)
HK (1) HK1209725A1 (pt)
MX (1) MX365192B (pt)
RU (1) RU2695383C2 (pt)
UA (1) UA117809C2 (pt)
WO (1) WO2013189847A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6262246B2 (ja) 2012-11-12 2018-01-17 イグニタ、インク． ベンダムスチン誘導体およびこれを使用する方法
EP2886536A1 (en) * 2013-12-19 2015-06-24 Helmut Schickaneder Bendamustine derivatives as anti-proliferative agents
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
JP2021502401A (ja) 2017-11-13 2021-01-28 エコラボ ユーエスエー インコーポレイティド ２−置換ベンズイミダゾールの大規模製造のための新規ワンポット均一プロセス

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD34727A1 (de) * 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
US5691371A (en) 1993-05-25 1997-11-25 Auckland Uniservices Limited Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CA2621470A1 (en) * 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
JP5773874B2 (ja) 2008-10-08 2015-09-02 セファロン、インク． ベンダムスチンの調製方法
EP2635558A4 (en) * 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
EP2656843B1 (en) * 2012-04-26 2015-03-18 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof

Also Published As

Publication number Publication date
ES2694757T3 (es) 2018-12-27
KR101955065B1 (ko) 2019-03-06
JP2015520200A (ja) 2015-07-16
CA2875455A1 (en) 2013-12-27
US10526290B2 (en) 2020-01-07
US20170313663A1 (en) 2017-11-02
US10294208B2 (en) 2019-05-21
WO2013189847A1 (en) 2013-12-27
CN104395296A (zh) 2015-03-04
BR112014031556A2 (pt) 2015-12-22
EP2861564A1 (en) 2015-04-22
MX2014014895A (es) 2015-06-17
KR20150020581A (ko) 2015-02-26
RU2695383C2 (ru) 2019-07-23
US20150152066A1 (en) 2015-06-04
JP6153606B2 (ja) 2017-06-28
UA117809C2 (uk) 2018-10-10
CA2875455C (en) 2020-03-10
EP2861564B1 (en) 2018-08-08
RU2014146896A (ru) 2016-08-10
BR112014031556B1 (pt) 2019-10-29
MX365192B (es) 2019-05-23

Similar Documents

Publication Publication Date Title
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
IL238662A (en) Bandostatin derivatives, containing them and used to treat cancer
HK1192758A1 (zh) '- 用於治療癌症的 -氟- '-脱氧尿苷的氨基磷酸酯衍生物
IL231386A (en) Pyrazolequinoline derivatives, their preparation and medical use
EP2906208A4 (en) THERAPEUTIC TREATMENT
EP2537530A4 (en) RADIOTHERAPY AGENT
IL239007B (en) Eribulin for use in the treatment of breast cancer
EP3071280A4 (en) TREATMENT CATHETER COMPRISING THE ADMINISTRATION OF THERAPEUTIC ENERGY
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EP2863983B8 (en) Medical therapy arrangement
HK1207013A1 (en) Catheter for photodynamic therapy
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
HK1209725A1 (en) Bendamustine derivatives and related compounds, and medical use thereof cancer therapy
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
SI2656843T1 (sl) Estri bendamustina in povezane spojine ter njihova medicinska uporaba
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
HK1209127A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
HK1213475A1 (zh) 用於癌症治療的 、卡培他濱和奧沙利鉑的組合
EP2817004A4 (en) BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES
EP2905284A4 (en) PHOTOSENSITIZATION TARGETING THYMIDINE KINASE AND PHARMACEUTICAL COMPOSITION AND USE FOR THE TREATMENT OF ASSOCIATED CANCER
IL233495A0 (en) Combination for cancer treatment
IL239231A0 (en) Combined cancer treatment
GB201222544D0 (en) Photodynamic therapy and diagnosis
HUP1200530A2 (en) Medical splint

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230608